Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib

Next Previous
Trial Profile

A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary) ; Savolitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms SAVANNAH
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 05 Sep 2025 According to a HUTCHMED media release, the company announced that data from this study will be presented at the 2025 World Conference on Lung Cancer (WCLC) taking place on Sunday, September 7, 2025 3:15 to 4:30PM CEST and Monday, September 8, 2025 in Barcelona, Spain.
  • 23 May 2025 According to HUTCHMED media release, the data of this trial will be presented at the American Society of Clinical Oncology Annual Meeting
  • 30 Apr 2025 Results(n=259) among pts with detected EGFRm ctDNA at BL, clearance at Wk 3 was associated with improved ORR and PFS. Plasma EGFRm clearance at Wk 3 is enriched in pts with MET IHC3+/≥90% or FISH10+ status, consistent with improved efficacy in this biomarker subgroup were presented at the 116th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top